In terms of provisions of Regulation 30 (read with Part A of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), this ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories held a board meeting on 11th November 2025 where it noted the passing of Non-Executive Director Dr. Mani L.S. (DIN 00825886) and expressed condolences. The Board appointed Mrs. Vijaya Mani (DIN 11363910) as an Additional Non-Executive Director with effect from 11th November 2025, subject to shareholder approval. She has not been debarred by SEBI or any authority from holding a director position. All four board committees — Audit, Nomination & Remuneration, Stakeholders' Relationship, and Risk Management — were reconstituted, with Mrs. Vijaya Mani being inducted into all of them and made Chairman of the Risk Management Committee.
The death of a sitting director and the immediate appointment of a new Non-Executive Director (likely a family member based on the shared surname) means governance continuity is maintained but shareholders will need to approve the new appointment at the next general meeting. Investors should watch for the outcome of that vote and assess whether board independence is preserved given her placement on multiple committees.